Psychosocial Support May Reduce Stigma for Patients With Lung Cancer
Because of the relationship between cigarette smoking and lung cancer, patients who receive a lung cancer diagnosis may feel judgment compared to patients with other cancer diagnoses, which could affect social interactions between family, caregivers, and healthcare professionals. Perceived lung cancer stigma can lead to depression, anxiety, poor self-esteem, guilt, shame, blame, poor social identity, and reduced social support. A recent study indicated that lung cancer stigma might be behind the low lung cancer screening rates among high-risk smokers.
FDA Approves Lorlatinib for Second, Third-Line Treatment of ALK-Positive Metastatic NSCLC
On November 2, 2018, the U.S. Food and Drug Administration (FDA) granted accelerated approval to lorlatinib (Lorbrena) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
FDA Cracks Down on Vaping Pods Because of High Nicotine Levels in Young Users
In September 2018, the U.S. Food and Drug Administration (FDA) issued more than 1,100 warning letters and fines to retailers and issued 131 fines for selling vaping pod products to minors. The agency also told manufacturers that the industry has 60 days to provide a plan to limit underage access to these products or face penalties.
First-Line Osimertinib for Metastatic Non-Small Cell Lung Cancer
Lung cancer is the second most common cancer in both men and women (after skin cancer) and is the leading cause of cancer death among both men and women. Histology has become an important determinant in choosing therapy for various types of cancer, including non-small cell lung cancer (NSCLC). Currently, biomarker testing is the standard of care in lung cancer; with biomarker testing, patients likely to respond to targeted therapy can be identified. As the number of targeted agents continues to increase, so does the demand for continued biomarker testing and adequate tumor tissue samples.
FDA Grants Nivolumab Accelerated Approval for Third-Line Treatment of Metastatic SCLC
On August 16, 2018, the U.S. Food and Drug Administration (FDA) granted accelerated approval to nivolumab for patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy.
Which of the Following Patient Types Is Not Indicated for Lung Cancer Screening With Low-Dose Helical Computed Tomography?
Which of the Following Patient Types Is Not Indicated for Lung Cancer Screening With Low-dose Helical Computed Tomography?
A. Is a current or former smoker
B. Is 55–74 years old
C. Has a 10–20 pack-year history
D. Has a 30 pack-year history but no signs or symptoms of lung cancer
Immunotherapy Plus Chemo Improves Survival in Metastatic Lung Cancer
Combining pembrolizumab and platinum chemotherapy plus pemetrexed doubles survival in patients with nonsquamous non-small cell lung cancer (NSNSCLC) without EGFR or ALK gene mutations, according to the results of a study published in the New England Journal of Medicine.
Patients Report More Satisfaction With Multidisciplinary Care Versus Serial Care for Lung Cancer
Despite the prevalence of multidisciplinary (MD) care for cancer, rigorous studies comparing it to serial care (SC) are lacking. To address the literature gap, researchers explored the use of MD versus SC for lung cancer and presented the findings at the 2018 American Society of Clinical Oncology Annual Meeting.
Tips for Creating a Multidisciplinary Research Team Focused on Symptom Management
Catherine Bender, PhD, RN, FAAN, of the University of Pittsburgh, and Amy Hoffman, PhD, RN, of Michigan State University, shared their experiences in building interdisciplinary research teams to assess symptom management during a session at the 43rd Annual Congress in Washington, DC.
Immunotherapy Opens New Frontiers in Lung Cancer Care
The development of targeted therapies brought new progress to lung cancer treatment and research in the past 20 years, and new options will continue to be available in the future. Roy Herbst, MD, PhD, director of thoracic oncology research program at the Yale Comprehensive Cancer Center at Yale School of Medicine in New Haven, CT, spoke at the 43rd Annual Congress in Washington, DC, on new standards of care for non-small cell lung cancer (NSCLC), immunotherapy for NSCLC, and development of rational drug combinations using biomarkers.
Regular Exercise May Improve Outcomes in Patients With Lung Cancer
In addition to lowering cancer risk, regular exercise before lung cancer surgery may improve postoperative outcomes, especially in lung cancer, according to the results of a literature review published in the British Journal of Sports Medicine.
Despite Awareness, 20% of American Adults Use Tobacco Products
It’s been 20 years since a panel of tobacco executives stood before Congress and admitted that their products were both addictive and linked to cancer. Since then, Americans have shifted their understanding about the use of tobacco products in ways not previously thought possible. These changes in perception and behavior are due in part to the public health initiatives and anti-tobacco campaigns of the last two decades.
FDA Grants Marketing Approval to FoundationOne CDx In Vitro Diagnostic
On November 30, 2017, the U.S. Food and Drug Administration granted marketing approval to the FoundationOne CDx, a next generation sequencing based in vitro diagnostic to detect genetic mutations in 324 genes and two genomic signatures in any solid tumor type.
Study Finds How Smoking Contributes to Epigenetics of Lung Cancer
Although cigarette use has long been linked to lung cancer, scientists have not understood how the earliest changes in lung cells developed. In a study published in Cancer Cell, researchers showed how cigarette smoke sensitized airway cells to genetic mutations that are known to cause lung cancers.
FDA Approves Alectinib for ALK-Positive, Advanced, Metastatic NSCLC
On November 6, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to alectinib (Alecensa) for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.
Recent Drug Approvals Offer New Options for Non-Small Cell Lung Cancer, Genitourinary Cancers, and More
Cancer treatment options continue to multiply as 2017 continues, with the U.S. Food and Drug Administration (FDA) granting multiple new drug approvals and broadening indications for others. Oncology clinicians and nurses are challenged with staying abreast of treatment option expansions and navigating the dynamic field of cancer treatment to effectively navigate their patients through the treatment trajectory, educating on vital points relative to treatment, minimizing morbidity and mortality, and optimizing quality of life. Following is an overview of the latest approvals for the second quarter of 2017.
Dendritic Cell Vaccine Uses Immune System to Fight NSCLC
A new study testing a dendritic cell vaccine for the first time in humans to treat non-small cell lung cancer (NSCLC) has shown that it successfully amplifies the immune system to boost the effectiveness of anti-PD-1 immunotherapies against the cancer. The findings were published in Clinical Cancer Research.
“Light” Cigarettes to Blame for Rise in Lung Adenocarcinoma
High-ventilation (light) cigarettes have no health benefits to smokers and have likely contributed to increased incidence of adenocarcinoma deep in the lungs, according to the results of a new study published in the Journal of the National Cancer Institute.
FDA Broadens Ceritinib Indication to Previously Untreated ALK-Positive Metastatic NSCLC
On May 26, 2017, the U.S. Food and Drug Administration granted regular approval to ceritinib (Zykadia®, Novartis Pharmaceuticals Corp.) for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
FDA Grants Accelerated Approval to Pembrolizumab in Combination With Pemetrexed and Carboplatin for Treatment of Metastatic Non-Squamous NSCLC
On May 10, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with pemetrexed and carboplatin for the treatment of patients with previously untreated metastatic non-squamous non-small cell lung cancer.
FDA Grants Accelerated Approval to Brigatinib for ALK-Positive NSCLC
On April 28, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to brigatinib for the treatment of patients with metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
Recent FDA-Approved Drugs Offer More Options for NSCLC and Other Cancers
The end of 2016 proved to be a busy and exciting time for cancer breakthroughs, seeing eight new U.S. Food and Drug Administration (FDA) approvals for immunotherapy and biotherapy. Following is a summary of cancer-related FDA approvals in the last quarter of 2016, indications for treatment, and associated clinical implications.
Cancer Deaths Fall 25% Since 1991
Research, treatment, and technology surges throughout the 1990s have led to a 25% reduction in cancer mortality rates since 1991, according to the American Cancer Society’s (ACS’s) latest Cancer Statistics, 2017, report (Siegel, Miller, & Jemal, 2016). The decline in cancer-related deaths accounts for more than 2.1 million lives saved between 1991 and 2014.